Sonnet Biotherapeutics announced positive topline safety data from its Phase 1 SB101 trial for SON-1010, showing a maximum tolerated dose of 1200 ng/kg with 48% of evaluable patients achieving stable disease at four months, including one patient with a 45% tumor size reduction.